Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape. Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 11 and 8 molecules, respectively.Leishmaniasis (Kala-Azar). Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Leishmaniasis (Kala-Azar) Overview 10 Therapeutics Development 11 Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11 Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12 Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13 Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 15 Leishmaniasis (Kala-Azar) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Leishmaniasis (Kala-Azar) - Products under Development by Companies 20 Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 21 Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 22 Advinus Therapeutics Ltd 22 BioLingus AG 23 iCo Therapeutics Inc. 24 Laboratorios LETI S.L. 25 ManRos Therapeutics 26 Matinas BioPharma Holdings, Inc. 27 Nanomerics Ltd 28 Novartis AG 29 Oblita Therapeutics BVBA 30 Leishmaniasis (Kala-Azar) - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Combination Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 (gentamicin sulfate + paromomycin sulfate) - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 18-MC - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 amphotericin B - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 amphotericin B - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 amphotericin B - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 amphotericin B - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Amphotericin B sodium - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 candicidin - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 CDRI-99288 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 D-121 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 GNF-6702 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 hypoestoxide - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 interferon gamma - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 KVH-14 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 leishmaniasis vaccine - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 leishmaniasis vaccine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 leishmaniasis vaccine - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 leishmaniasis vaccine - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 leishmaniasis vaccine 2 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 NPC-1161B - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 P-MAPA - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Peptides for Infectious Diseases - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 S-010269 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 SJL-01 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Small Molecule for Leishmaniasis - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Small Molecule for Leishmaniasis - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Small Molecule for Visceral Leishmaniasis - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Small Molecules for Infectious Diseases - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Small Molecules for Infectious Diseases - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Small Molecules for Leishmaniasis - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Small Molecules for Leishmaniasis - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Small Molecules for Visceral Leishmaniasis - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 Small Molecules for Visceral Leishmaniasis - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease and Leishmaniasis - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Synthetic Peptides for Infectious Disease - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Vaccine for Leishmaniasis - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 visceral leishmaniasis vaccine - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Leishmaniasis (Kala-Azar) - Dormant Projects 90 Leishmaniasis (Kala-Azar) - Discontinued Products 92 Leishmaniasis (Kala-Azar) - Product Development Milestones 93 Featured News & Press Releases 93 Dec 15, 2015: U.S. Issues Patent on Corifungin 93 Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 93 Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 93 Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 94 Feb 26, 2013: National Institutes of Health Supports Acea's Research 95 Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee 95 Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 96 Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 97 Jul 01, 2011: FDA issues orphan-drug designation to Corifungin 98 Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 98 Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC 99 Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102
List of Tables
Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016 11 Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Comparative Analysis by Unknown Stage Development, H2 2016 19 Products under Development by Companies, H2 2016 20 Products under Investigation by Universities/Institutes, H2 2016 21 Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd, H2 2016 22 Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H2 2016 23 Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H2 2016 24 Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI S.L., H2 2016 25 Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H2 2016 26 Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 27 Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H2 2016 28 Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H2 2016 29 Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H2 2016 30 Assessment by Monotherapy Products, H2 2016 31 Assessment by Combination Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 36 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2016 90 Leishmaniasis (Kala-Azar) - Dormant Projects (Contd..1), H2 2016 91 Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2016 92
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
